EDMONTON, AB — February 3, 2026 — Leads & Copy —
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a Canadian-based global medical cannabis company, has launched four new websites to support key European markets. This continues its investment in the region through a focused, locally relevant digital presence.
The refreshed platforms reflect Aurora’s science-backed approach, manufacturing expertise, and brand strength, while improving engagement with healthcare professionals, partners, and prospective employees across Europe.
According to Andreas Dotterweich, Senior Vice President, Aurora Europe, the new European websites demonstrate the company’s ongoing investment and long-term commitment to the region, Aurora’s fastest growing.
Dotterweich added that the sites leverage Aurora’s global leadership in medical cannabis, putting its products, scientific expertise, and partnerships front and center, providing enhanced resources for healthcare practitioners and partners looking for a trusted resource. He believes this streamlined digital presence across Europe positions Aurora to drive growth, reinforce its leadership, and deliver lasting value in Europe.
The central European site, www.auroramedicine.com, provides easy access to the dedicated regional sites for Germany, the UK, and Poland.
Building on the recent evolution of Aurora’s global brand identity, the new regional websites showcase manufacturing excellence, highlighting both Canadian-made and local production through updated videos and photos. The sites emphasize quality, compliance, and evidence-based processes.
Each platform is available in the native language of its market, and all regional sites are seamlessly accessible from the drop-down menu on the central European hub.
The new websites enhance the experience for healthcare practitioners and partners across Europe. Aligned with Aurora’s broader European communications strategy, they establish a locally relevant platform that strengthens engagement, showcases the company’s leadership, and positions Aurora to capture emerging opportunities in the evolving medical cannabis market.
Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora’s portfolio of brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty’s™ and Whistler Cannabis Co™. The company also holds a controlling interest in Bevo Farms Ltd.
Aurora’s common shares trade on the NASDAQ and TSX under the symbol “ACB”.
Learn more at www.auroramj.com and follow on X and LinkedIn.
Source: Aurora Cannabis Inc.
